The UK’s medicine regulator says anyone with a history of anaphylaxis for medication or food should not take the Pfizer-Bioentech vaccine, which extends its guidance on allergy warning about shots, the first approval against COVID-19.
“Anyone with a history of anaphylaxis for a vaccine, drug or diet should not take the Pfizer Bioentech vaccine,” said John Raine, chief executive of the Medicines and Healthcare Products Regulatory Agency (MHRA), in a statement. “Anyone experiencing anaphylaxis following the administration of the first dose of this vaccine should not be given a second dose.”
The United Kingdom became the first country in the world to start vaccination against COVID-19 this week, but on the first day of the mass vaccination program, people with their shots were warned of “significant allergic reactions” after reports of three possible allergic reactions. Inoculation should not be taken.
The previous warning did not mention anaphylaxis, a serious and potentially fatal reaction to a trigger, usually foods including milk, nuts and shellfish, as well as drugs such as aspirin. Other triggers include bee stings and latex.
Symptoms of anaphylaxis include dizziness, shortness of breath, and rapid heartbeat. The patient may also have rashes. The reaction requires immediate treatment and many people who suffer from severe allergies usually take an adrenaline auto toe-injector.
The MHRA on Tuesday approved the Pfizer-Bioentech vaccine for emergency use last week, paving the way for the launch of a UK-wide vaccination program.
The agency said it was updating its guidance after two cases of post-vaccination anaphylaxis and one report of a possible allergic reaction.
“Most people will not get anaphylaxis and the benefits of protecting people against COVID-19 outweigh the risks,” Ryan insisted.
“You can be absolutely sure that this vaccine meets the strong standards of safety, quality and effectiveness of MHRA. Safety data has also been criticized by the government’s Independent Advisory Council, the Human Drugs Commission. No vaccine will be approved until it meets these strict standards – you can be sure of that. “
More approvals
Canada is the advanced country to approve the Pfizer-Bioentech vaccine, which has shown a 95 percent effectiveness in late-stage trials, raising hopes that it will help end the coronavirus epidemic. Bahiri has also authorized the vaccine for public use, while the U.S. The Food and Drug Administration is set to consider emergency use authorization on Thursday.
On Twitter, New York Governor Rev. Andrew Cuomo said the drug would be approved by the FDA and the state’s own panel would then “review and approve.” About 170,000 doses could arrive in New York by the end of the week, he said on Twitter.
Seventy UK hospitals are involved in the Pfizer-Biontech campaign with the first dose given to people over the age of 80.
Margaret Keenan, 90, was the first patient in the UK to receive the Pfizer-Bioentech COVID-19 vaccine. [Jacob King/Pool via AP Photo]
With a population of around 67 million people, the UK has more deaths from Covid-1 than anywhere else in Europe, and has confirmed more than 1.7 million cases of the disease.
He has ordered 40 million doses of the vaccine, which need to be sent and stored at -70 સે C (-94 F) or below. The order to inoculate 20 million people is enough, because apart from 21 days, the vaccine has to be given in two injections.
U.S. There are many other vaccines in development with the expectation of an emergency clearance in the next few weeks with Moderna based. The vaccine has been developed in partnership with the National Institutes of Health in the United States, and it uses a similar basic approach to Pfizer-Bioentech shots.
Scientists at Oxford University in the UK, meanwhile, expect their COVID-19 vaccine to report results by Christmas through late-stage tests. He is working with the UK-based pharmaceutical company AstraZeneca. The experimental vaccine is expected to be cheaper and easier to handle than Pfizer and Moderna shots.
.
